26.5 USD
-0.18 (-0.67%)
26.5 USD
0 (0%)
Taking everything into account, BLFS scores 5 out of 10 in our fundamental rating. BLFS was compared to 58 industry peers in the Life Sciences Tools & Services industry. BLFS has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, BLFS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BLFS was profitable.
BLFS had a positive operating cash flow in the past year.
In the past 5 years BLFS reported 4 times negative net income.
In multiple years BLFS reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of -0.82%, BLFS is doing good in the industry, outperforming 60.34% of the companies in the same industry.
The Return On Equity of BLFS (-0.91%) is better than 67.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLFS's Gross Margin of 70.02% is amongst the best of the industry. BLFS outperforms 93.10% of its industry peers.
In the last couple of years the Gross Margin of BLFS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLFS has been increased compared to 1 year ago.
BLFS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BLFS has an improved debt to assets ratio.
2.2 Solvency
BLFS has an Altman-Z score of 19.27. This indicates that BLFS is financially healthy and has little risk of bankruptcy at the moment.
BLFS has a better Altman-Z score (19.27) than 100.00% of its industry peers.
BLFS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.27 |
ROIC/WACCN/A
WACC10.09%
2.3 Liquidity
BLFS has a Current Ratio of 4.66. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS has a Current ratio of 4.66. This is in the better half of the industry: BLFS outperforms 72.41% of its industry peers.
BLFS has a Quick Ratio of 3.64. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS's Quick ratio of 3.64 is fine compared to the rest of the industry. BLFS outperforms 65.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 123.36% over the past year.
BLFS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.98%.
The Revenue has been growing by 24.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
3.2 Future
The Earnings Per Share is expected to grow by 29.91% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.24% on average over the next years. This is quite good.
EPS Next Y28%
EPS Next 2Y47.99%
EPS Next 3Y43.26%
EPS Next 5Y29.91%
Revenue Next Year-5.39%
Revenue Next 2Y4.22%
Revenue Next 3Y9.87%
Revenue Next 5Y16.24%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 106.00, which means the current valuation is very expensive for BLFS.
Compared to the rest of the industry, the Price/Earnings ratio of BLFS is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.31, BLFS is valued quite expensively.
BLFS is valuated quite expensively with a Price/Forward Earnings ratio of 273.48.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BLFS is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, BLFS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 106 | ||
| Fwd PE | 273.48 |
4.2 Price Multiples
BLFS's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 243.03 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLFS does not grow enough to justify the current Price/Earnings ratio.
BLFS's earnings are expected to grow with 43.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.79
PEG (5Y)N/A
EPS Next 2Y47.99%
EPS Next 3Y43.26%
5. Dividend
5.1 Amount
No dividends for BLFS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.5
-0.18 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.58%
Inst Owner Change-2.67%
Ins Owners2.2%
Ins Owner Change-0.86%
Market Cap1.28B
Revenue(TTM)88.83M
Net Income(TTM)-3.21M
Analysts83.75
Price Target32.74 (23.55%)
Short Float %6.55%
Short Ratio8.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.28%
Min EPS beat(2)72.55%
Max EPS beat(2)184.01%
EPS beat(4)4
Avg EPS beat(4)208.62%
Min EPS beat(4)72.55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)84.53%
EPS beat(12)8
Avg EPS beat(12)5.02%
EPS beat(16)10
Avg EPS beat(16)1.09%
Revenue beat(2)2
Avg Revenue beat(2)6.11%
Min Revenue beat(2)5.11%
Max Revenue beat(2)7.1%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.34%
Max Revenue beat(4)7.1%
Revenue beat(8)7
Avg Revenue beat(8)8.78%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.21%
PT rev (1m)2.56%
PT rev (3m)2.56%
EPS NQ rev (1m)-50.06%
EPS NQ rev (3m)12.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.53%
Revenue NQ rev (1m)-6.17%
Revenue NQ rev (3m)-7.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 106 | ||
| Fwd PE | 273.48 | ||
| P/S | 14.29 | ||
| P/FCF | N/A | ||
| P/OCF | 75.37 | ||
| P/B | 3.59 | ||
| P/tB | 9.48 | ||
| EV/EBITDA | 243.03 |
EPS(TTM)0.25
EY0.94%
EPS(NY)0.1
Fwd EY0.37%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.35
OCFY1.33%
SpS1.85
BVpS7.38
TBVpS2.8
PEG (NY)3.79
PEG (5Y)N/A
Graham Number6.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% | ||
| FCFM | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 298.5% | ||
| Cap/Sales | 19.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 353.72% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 19.27 |
F-Score6
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y28%
EPS Next 2Y47.99%
EPS Next 3Y43.26%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
Revenue Next Year-5.39%
Revenue Next 2Y4.22%
Revenue Next 3Y9.87%
Revenue Next 5Y16.24%
EBIT growth 1Y95.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y97.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y342.36%
OCF growth 3YN/A
OCF growth 5Y47.44%
BIOLIFE SOLUTIONS INC / BLFS FAQ
What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BLFS.
What is the valuation status for BLFS stock?
ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.
Can you provide the profitability details for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 3 / 10.
What is the financial health of BIOLIFE SOLUTIONS INC (BLFS) stock?
The financial health rating of BIOLIFE SOLUTIONS INC (BLFS) is 8 / 10.
Can you provide the dividend sustainability for BLFS stock?
The dividend rating of BIOLIFE SOLUTIONS INC (BLFS) is 0 / 10 and the dividend payout ratio is 0%.